Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 CAD | +1.30% | +4.70% | -12.85% |
04-11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
04-11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Sales 2024 * | 750K 548K 43.78M | Sales 2025 * | 5.72M 4.18M 334M | Capitalization | 116M 84.84M 6.78B |
---|---|---|---|---|---|
Net income 2024 * | -35M -25.57M -2.04B | Net income 2025 * | -40M -29.22M -2.33B | EV / Sales 2024 * | 155 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 20.3 x |
P/E ratio 2024 * |
-3.51
x | P/E ratio 2025 * |
-3.57
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.1% |
Latest transcript on Oncolytics Biotech Inc.
1 day | +1.30% | ||
1 week | +4.70% | ||
Current month | +1.96% | ||
1 month | +9.86% | ||
6 months | -35.80% | ||
Current year | -12.85% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 10/05/11 |
Kirk Look
DFI | Director of Finance/CFO | - | 31/03/03 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 06/09/22 |
Patricia Andrews
BRD | Director/Board Member | 66 | 01-08 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 07/06/15 |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 1.56 | +1.30% | 8 399 |
01/05/24 | 1.54 | +0.65% | 69,935 |
30/04/24 | 1.53 | +2.00% | 11,088 |
29/04/24 | 1.5 | +2.04% | 31,243 |
26/04/24 | 1.47 | -1.34% | 14,646 |
Delayed Quote Toronto S.E., May 02, 2024 at 05:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.85% | 84.41M | |
+22.15% | 42.68B | |
-3.43% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.73% | 24.94B | |
-19.89% | 18.96B | |
+29.39% | 12.3B | |
-2.88% | 11.95B | |
-1.75% | 11.55B |
- Stock Market
- Equities
- ONC Stock